GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.
about
The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging ratsEyeblink Conditioning and Novel Object Recognition in the Rabbit: Behavioral Paradigms for Assaying Psychiatric DiseasesThe impact of hippocampal lesions on trace-eyeblink conditioning and forebrain-cerebellar interactionsRats selectively bred for low levels of play-induced 50 kHz vocalizations as a model for autism spectrum disorders: a role for NMDA receptorsNMDA receptor modulators: an updated patent review (2013-2014)GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonistsA brief history of the development of antidepressant drugs: from monoamines to glutamateGLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.Antibody therapeutics targeting ion channels: are we there yet?GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Attenuates Cerebral Ischemia Injury In Vivo and Vitro by Differential Modulations of NMDA Receptors Subunit Components at Different Post-Ischemia Stage in MiceThe IGF-derived tripeptide Gly-Pro-Glu is a weak NMDA receptor agonistGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.Investigational drugs for treating major depressive disorder.Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors.PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis.Evoking blinks with natural stimulation and detecting them with a noninvasive optical device: a simple, inexpensive method for use with freely moving animalsGene expression patterns in hypoxic and post-hypoxic adult rat retina with special reference to the NMDA receptor and its interactome.A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus.Synaptic Plasticity, Metaplasticity and Depression.Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).Novel N-methyl-D-aspartate receptor antagonists: a review of compounds patented since 2006.Novel glutamatergic drugs for the treatment of mood disorders.Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disordersNMDA antagonists under investigation for the treatment of major depressive disorder.The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.Targeted gene transfer of different genes to presynaptic and postsynaptic neocortical neurons connected by a glutamatergic synapse.BDNF release and signaling are required for the antidepressant actions of GLYX-13.NYX-2925 is a novel NMDA receptor-specific spirocyclic-β-lactam that modulates synaptic plasticity processes associated with learning and memory.Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1.Convergent Mechanisms Underlying Rapid Antidepressant Action.Commentary: GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1
P2860
Q24629141-AE997DE7-9B37-4C7C-BD6E-D0D687A0A4E5Q26779267-D7812A42-E563-4D48-BCDD-E8F8AE6512E0Q26799293-9E1E1882-F6BF-4735-8D7A-577A0ABEF86FQ26866047-33918F25-BC0E-4382-9F56-9EFDCEDDCF09Q26997407-01583543-A92F-4949-BD0F-E9940705FF95Q27025974-2B435976-1797-4CA7-8803-072ADFDC8265Q27028050-C76FA7C0-38FF-4EE5-8468-6C6D04351260Q30440925-5AD7B9F0-BE1C-4581-9896-203E602CA146Q30695515-16018F7C-AD24-40C6-8378-E89B4EFB55D5Q33572352-2EDF5091-682E-4189-8E44-58E7A611152BQ33780749-98C840D0-9BA7-4EF3-8D2F-49B272AA5D11Q34063244-DCC0990A-7AF5-4AA3-9106-A9241E381EA8Q34330678-2BC17DDD-91AE-4CC7-9388-01E247279ECFQ34519141-DD5CECB3-3277-47F2-9E58-91CF9F9D3A24Q34547274-F6F90ED1-1A29-43A0-A2A2-198D679710B0Q35194637-4D350ED0-0FB6-4663-83E8-A01B16E9DF66Q35224315-BC01C21E-076F-4CA0-9350-11258DD05FE8Q36310524-CFFE11A2-7A06-449B-96FD-9036BAA51194Q36486035-186CE1F4-4B01-41CD-BFDE-243D9A5EBB27Q36548721-E9F65F9C-7EF9-4E63-84D2-2F5F2EB6C0FEQ36935216-6C10FB98-B83E-4758-98BF-28094AF3A68AQ37083763-96B93CA3-0882-4BA5-8546-FDC2A094E23FQ37141200-D8AE3676-4382-4641-A303-DFB0E319D7ACQ37668039-75311AFC-BC0B-4189-9B5F-AD595D5B6894Q37741989-436ED8D7-F5A6-46FE-8C8D-436208EA2D38Q37807432-85E9FE6A-2D29-4A0A-8459-D4D155301938Q38131480-D2856CDB-0D6D-442A-8624-6D78E588EC07Q38194145-BF2B3199-F2CE-4375-A7B8-157BFF80F2F1Q38211107-ABCBAF95-F9FB-4FC9-A1A1-E672FC01254CQ40569480-1268FB0A-90FB-4A99-85EA-BC2AAFFF2377Q41810323-0FC9BF00-3A33-4B1F-906B-0D73D8006AA6Q47331962-8DE37D09-B8CB-4C81-8F5B-8DB253170C9EQ47383734-3243C72A-6500-4670-8A66-9F4D721757A9Q47388230-C9E63A79-1BF3-4A05-AE0E-A3E91F394D9DQ47963007-2CD6C9E3-D84C-4CB0-B972-CBD89DB9CB4BQ48472517-AA6E3690-A57B-4AA3-A43C-F1AA9A8B934FQ52562685-B1486418-0681-4802-A4DD-43A1263C57DCQ52667723-A3E4A0A5-EDB5-4DB8-90EF-BCE4415AE36DQ58762928-36ECFFE2-AD65-4BFA-8F82-0AC1ABE85C20
P2860
GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@ast
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@en
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@nl
type
label
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@ast
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@en
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@nl
prefLabel
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@ast
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@en
GLYX-13: a monoclonal antibody ...... -aspartate receptor modulator.
@nl
P2093
P1433
P1476
GLYX-13: a monoclonal antibody ...... D-aspartate receptor modulator
@en
P2093
Amy O'Connor Hanson
Craig Weiss
Joseph R Moskal
Paul L Wood
Robert B Harris
Stephen Kelso
P304
P356
10.1016/J.NEUROPHARM.2005.06.006
P577
2005-07-26T00:00:00Z